AptaBio Therapeutics Inc. (KOSDAQ:293780)

South Korea flag South Korea · Delayed Price · Currency is KRW
10,050
-390 (-3.74%)
Jul 18, 2025, 3:30 PM KST
-14.76%
Market Cap270.16B
Revenue (ttm)3.11B
Net Income (ttm)-27.82B
Shares Out26.88M
EPS (ttm)-1,126.65
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,151,427
Average Volume881,589
Open10,440
Previous Close10,440
Day's Range9,640 - 10,650
52-Week Range5,750 - 14,560
Beta1.57
RSI65.33
Earnings DateAug 14, 2025

About AptaBio Therapeutics

AptaBio Therapeutics Inc., a biopharmaceutical company, develops platform based drugs for intractable diseases. Its platforms include Oxidative stress modulation platform for developing therapeutic agents for diabetes complications, vascular diseases, neurodegenerative diseases, and intractable cancers by controlling oxidative stress; Cancer-associated fibroblast control platform for developing new anticancer drugs for intractable cancer; and Aptamer-drug conjugate platform for developing intractable anticancer drugs with high unmet medical nee... [Read more]

Sector Healthcare
Founded 2009
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 293780
Full Company Profile

Financial Performance

In 2024, AptaBio Therapeutics's revenue was 3.36 billion, an increase of 937.76% compared to the previous year's 323.87 million. Losses were -29.38 billion, 147.6% more than in 2023.

Financial Statements

News

There is no news available yet.